ACRO Biomedical wins India approval for collagen matrix

ACRO Biomedical said it has secured Indian regulatory approval for its ABCcolla Collagen Matrix and will showcase its regenerative medicine portfolio at Medicall Exhibition in Booth 2B23. The company is also advancing approval for a collagen bone matrix and a corneal-ulcer trial in India, signaling a deeper push into one of the world’s biggest healthcare markets.

Why it matters: - India approval gives ACRO Biomedical a clearer path into a major medical device market. - The company is positioning its collagen-based regenerative products for use in wound care, orthopedics, dentistry, ophthalmology and reconstructive surgery. - A broader India presence could support commercialization of additional products now in review or clinical development.

What happened: - ACRO Biomedical said the Central Drugs Standard Control Organisation and the Drugs Controller General of India approved its ABCcolla Collagen Matrix. - The company will present the product and its broader regenerative medicine portfolio at Medicall Exhibition at Booth 2B23. - ACRO Biomedical is operating in India through its local subsidiary. - The company is also seeking approval for its ABCcolla Collagen Bone Matrix. - ACRO Biomedical is advancing its ABCcolla Ophthalmic Matrix and is running a large-scale clinical trial in 150 patients to treat all types of corneal ulcers.

The details: - ACRO Biomedical said a clinical trial in Taiwan was recently completed before the larger 150-patient study began. - Chairman and CEO Dar-Jen Hsieh said the company’s proprietary extraction technology is designed to create highly biocompatible and safe collagen scaffolds. - Hsieh said the India approvals and ophthalmic trial are significant milestones in ACRO Biomedical’s mission to improve patient outcomes worldwide. - The company was founded in 2014 and is based in Kaohsiung Science Park in Taiwan. - ACRO Biomedical uses a patented Supercritical Carbon Dioxide Decellularization Technology. - The process produces collagen scaffolds without chemical cross-linkers. - The company’s product lineup includes ABCcolla Collagen Matrix, ABCcolla Bone Graft, ABCcolla Collagen Membrane and ABCcolla Ophthalmic Matrix. - ACRO Biomedical said those products serve wound care, orthopedics, dentistry, ophthalmology and reconstructive surgery.

Between the lines: - The India regulatory win suggests ACRO Biomedical is trying to turn its research and patent portfolio into a broader international sales strategy. - The ophthalmology program appears to be a key near-term growth driver, especially if the corneal-ulcer trial produces favorable results. - The Medicall appearance gives the company a venue to build clinical and commercial relationships as it expands in the region.

What's next: - ACRO Biomedical will use Medicall Exhibition to meet potential partners and present its latest devices. - The company will continue the approval process for ABCcolla Collagen Bone Matrix in India. - ACRO Biomedical will also continue the 150-patient study for ABCcolla Ophthalmic Matrix. - More information is available in the company's announcement.

The bottom line: - ACRO Biomedical is using an India approval, an active clinical program and an exhibition showcase to push deeper into regenerative medicine markets.